Evaluation of an Immunomodulatory Maintenance Treatment in Patients With Metastatic Colorectal Cancer With Tumor Reduction During Induction Treatment

Trial Profile

Evaluation of an Immunomodulatory Maintenance Treatment in Patients With Metastatic Colorectal Cancer With Tumor Reduction During Induction Treatment

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Lefitolimod (Primary)
  • Indications Carcinoma; Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPALA
  • Sponsors Mologen
  • Most Recent Events

    • 28 Nov 2017 According to a Mologen media release, data will be presented at the ESMO IO 2017 (European Society for Medical Oncology-Immuno Oncology) in Geneva.
    • 10 Aug 2017 According to a Mologen media release, The aim of the study is to verify whether what is known as switch maintenance therapy with the immunotherapy lefitolimod leads to a prolongation of overall survival. Analysis of the study is expected to begin in 2019.
    • 22 Jun 2017 Planned End Date changed from 1 Jun 2019 to 1 May 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top